Identifying CLL patients at high risk of atrial fibrillation on treatment using machine learning

References

• Kipps TJ, Choi MY. Targeted therapy in chronic lymphocytic leukemia. Cancer J. 2019;25(6):378–385. doi:10.1097/PPO.0000000000000416
   PubMed Web of Science ®Google Scholar
• Farooqui MZH, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16(2):169–176. doi:10.1016/S1470-2045(14)71182-9
   PubMed Web of Science ®Google Scholar
• Ahn IE, Tian X, Wiestner A. Ibrutinib for chronic lymphocytic leukemia with TP53 alterations. N Engl J Med. 2020;383(5):498–500. doi:10.1056/NEJMC2005943/SUPPL_FILE/NEJMC2005943_DISCLOSURES.PDF
   PubMed Web of Science ®Google Scholar
• Winqvist M, Asklid A, Andersson PO, et al. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the swedish chronic lymphocytic leukemia group. Haematologica. 2016;104(5):e208–e210. doi:10.3324/HAEMATOL.2016.144576
   Google Scholar
• Hillmen P, Rawstron AC, Brock K, et al. Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study. J Clin Oncol. 2019;37(30):2722–2729. doi:10.1200/JCO.19.00894
   PubMed Web of Science ®Google Scholar
• Deering KL, Sundaram M, Harshaw Q, et al. Health-related quality of life and treatment satisfaction in chronic lymphocytic leukemia (CLL) patients on ibrutinib compared to other CLL treatments in a real-world US cross sectional study. PLoS One. 2022;17(10):e0270291. doi:10.1371/JOURNAL.PONE.0270291
   PubMed Web of Science ®Google Scholar
• Goyal RK, Nagar SP, Kabadi SM, et al. Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: real-world evidence from the medicare population. Cancer Med. 2021;10(8):2690–2702. doi:10.1002/CAM4.3855
   PubMed Web of Science ®Google Scholar
• Varughese T, Taur Y, Cohen N, et al. Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer. Clin Infect Dis. 2018;67(5):687–692. doi:10.1093/cid/ciy175
   PubMed Web of Science ®Google Scholar
• Shatzel JJ, Olson SR, Tao DL, et al. Ibrutinib-associated bleeding; pathogenesis, management, and riskreduction strategies. J Thromb Haemost. 2017;15(5):835–847. doi:10.1111/JTH.13651
   PubMed Web of Science ®Google Scholar
• Caldeira D, Alves D, Costa J, et al. Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis. PLoS One. 2019;14(2):e0211228. doi:10.1371/JOURNAL.PONE.0211228
   PubMed Web of Science ®Google Scholar
• Aarup K, Rotbain EC, Enggaard L, et al. Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib. Eur J Haematol. 2020;105(5):646–654. doi:10.1111/EJH.13499
   PubMed Web of Science ®Google Scholar
• Mauro FR, Giannarelli D, Visentin A, et al. Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Cancers. 2021;13(13):3240. doi:10.3390/cancers13133240
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Parikh SA, Noseworthy PA, et al. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2016;58(7):1630–1639. doi:10.1080/10428194.2016.1257795
   PubMed Web of Science ®Google Scholar
• Visentin A, Deodato M, Mauro FR, et al. A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. Hematol Oncol. 2019;37(4):508–512. doi:10.1002/hon.2655
   PubMed Web of Science ®Google Scholar
• Schnabel RB, Sullivan LM, Levy D, et al. Development of a risk score for atrial fibrillation (framingham heart study): a community-based cohort study. Lancet. 2009;373(9665):739–745. doi:10.1016/S0140-6736(09)60443-8
   PubMed Web of Science ®Google Scholar
• Archibald WJ, Rabe KG, Kabat BF, et al. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. Ann Hematol. 2021;100(1):143–155. doi:10.1007/s00277-020-04094-3
   Google Scholar
• Vainer N, Aarup K, Andersen MA, et al. Real-world outcomes upon second-line treatment in patients with chronic lymphocytic leukaemia. Br J Haematol. 2023;201(5):874–886. doi:10.1111/bjh.18715
   PubMed Web of Science ®Google Scholar
• Da Cunha-Bang C, Geisler CH, Enggaard L, et al. The danish national chronic lymphocytic leukemia registry. Clin Epidemiol. 2016;8:561–565. doi:10.2147/CLEP.S99486
   PubMed Web of Science ®Google Scholar
• Persimune. Danish National Foundation for Research’s (DNRF) centre of excellence (COE) for personalised medicine of infectious complications in immune deficiency (PERSIMUNE). https://www.persimune.dk/.
   Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP; [cited 2023 May 31]. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50.
   Google Scholar
• Andersen MA, Moser CE, Lundgren J, et al. Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study. Leuk. 2018;33(3):662–670. doi:10.1038/s41375-018-0316-5
   PubMed Web of Science ®Google Scholar
• Agius R, Brieghel C, Andersen MA, et al. Machine learning can identify newly diagnosed patients with CLL at high risk of infection. Nat Commun. 2020;11(1):363. doi:10.1038/s41467-019-14225-8
   PubMed Web of Science ®Google Scholar
• Barnwal A, Cho H, Hocking T. Survival regression with accelerated failure time model in XGBoost. J Comput Graph Stat. 2022;31(4):1292–1302. doi:10.1080/10618600.2022.2067548
   Web of Science ®Google Scholar
• Pölsterl S. Scikit-survival: a library for time-to-event analysis built on top of scikit-learn. J Mach Learn Res. 2020;21:1–6.
   PubMed Web of Science ®Google Scholar
• Pedregosa F, Varoquaux G, Gramfort A, et al. Scikit-learn: machine learning in python. J Mach Learn Res. 2011;12(85):2825–2830. http://jmlr.org/papers/v12/pedregosa11a.html
   Google Scholar
• Conover WJ. Practical nonparametric statistics. 3rd ed. Wiley; 1999. http://gso.gbv.de/DB=2.1/CMD?ACT=SRCHA&SRT=YOP&IKT=1016&TRM=ppn+24551600X&sourceid=fbw_bibsonomy.
   Google Scholar
• Davidson-Pilon C. Lifelines: survival analysis in python. J Open Source Softw. 2019;4(40):1317. doi:10.21105/joss.01317
   Google Scholar
• Kater AP, Owen C, Moreno C, et al. Fixed-Duration ibrutinib-Venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid. 2022;1(7):6. doi:10.1056/EVIDOA2200006
   Google Scholar
• Kater AP, Levin MD, Dubois J, et al. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial. Lancet Oncol. 2022;23(6):818–828. doi:10.1016/S1470-2045(22)00220-0
   PubMed Web of Science ®Google Scholar
• Brown JR, Moslehi J, O'Brien S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102(10):1796–1805. doi:10.3324/haematol.2017.171041
   PubMed Web of Science ®Google Scholar
• Boos CJ. Infection and atrial fibrillation: inflammation begets AF. Eur Heart J. 2020;41(10):1120–1122. doi:10.1093/EURHEARTJ/EHZ953
   PubMed Web of Science ®Google Scholar
• Niemann CU. BTK inhibitors: safety + efficacy = outcome. Blood. 2023;142(8):679–680. doi:10.1182/BLOOD.2023020974
   PubMed Web of Science ®Google Scholar